Compositions and methods for treating CNS disorders
US12208103B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Feb 12, 2024 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Feb 12, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4825
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.